Crossref
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
AME Clinical Trials Review · 2023
DOI: 10.21037/actr-23-37 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Igor Gómez-Randulfe und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gómez-Randulfe, I., & Califano, R. (2023). The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-37
Vancouver
Gómez-Randulfe I, Califano R. The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-37
BibTeX
@article{GmezRandulfe2023,
author = {Gómez-Randulfe, Igor and Califano, Raffaele},
title = {The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer},
journal = {AME Clinical Trials Review},
year = {2023},
doi = {10.21037/actr-23-37}
}
EUVIMED